Docetaxel for Pembrolizumab-Refractory Recurrent Basal Cell Carcinoma.
0/5 보강
APA
Sakai Y, Ogata D, et al. (2026). Docetaxel for Pembrolizumab-Refractory Recurrent Basal Cell Carcinoma.. The Journal of dermatology. https://doi.org/10.1111/1346-8138.70244
MLA
Sakai Y, et al.. "Docetaxel for Pembrolizumab-Refractory Recurrent Basal Cell Carcinoma.." The Journal of dermatology, 2026.
PMID
41891435 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Minimally invasive surgery for right-sided colon cancer with superior mesenteric artery rotation: clinical features and short-term outcomes.
- The efficacy of metastasis-directed external beam radiotherapy for castration-resistant prostate cancer: A retrospective multicenter study.
- Discovering Anticancer Effects of Phytochemicals on MicroRNA in the Context of Data Mining.
- Phase I clinical study of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/stem (regenerative) cell.
- Gigantomastia induced by bucillamine.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Real-world Treatment Selection and Shared Decision-making in De Novo Metastatic Castration-sensitive Prostate Cancer in Japan.
- Histological and Genetic Markers of Cellular Senescence in Keratinocyte Cancers and Actinic Keratosis: A Systematic Review.
- Does Basal Cell Carcinoma Arise from a Precursor Lesion?
- Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform.
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.
- Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients.